BEAM
Beam Therapeutics Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +9 | 71.47M | $2.45B | +12 | −3 |
| Q1 2026 | 92 | +3 | 70.17M | $1.67B | +9 | −6 |
| Q4 2025 | 89 | +3 | 73.41M | $2.04B | +4 | −1 |
| Q3 2025 | 16 | -1 | 52.77M | $1.28B | +1 | −2 |
| Q2 2025 | 14 | 0 | 51.27M | $872.17M | +1 | −1 |
| Q1 2025 | 11 | -2 | 20.67M | $403.69M | — | −2 |
| Q4 2024 | 13 | +2 | 16.59M | $411.47M | +3 | −1 |
| Q3 2024 | 10 | -1 | 11.89M | $291.41M | — | −1 |
| Q2 2024 | 11 | — | 12.82M | $300.27M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 12.96M | — | $220.47M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | The Vanguard Group ✦ (passive) | 9.71M | — | $165.10M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 3 | ARK Investment Management ✦ | 8.85M | +4.3% | $150.50M | 1.1% | ▲ Add | 5 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 8.00M | — | $136.13M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 5 | State Street Global Advisors ✦ (passive) | 3.64M | +5.8% | $61.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.44M | -19.3% | $41.55M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 2.34M | -6.5% | $39.76M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Geode Capital Management ✦ (passive) | 2.25M | +2.5% | $38.35M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 561.52K | +52.1% | $9.55M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Baillie Gifford ✦ | 300.14K | -0.9% | $5.11M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
| 11 | Marshall Wace ✦ | 99.96K | -62.9% | $1.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 58.20K | +59.5% | $990,050 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Wellington Management ✦ | 37.27K | +10.8% | $633,912 | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 14 | AQR Capital Management ✦ | 25.42K | New | $432,411 | 0.0% | New | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $432,411 | 0.0% |
Exited
| Renaissance Technologies | $236,450 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 248 holders, 107.79M shares, $2.49B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 187 sh · $4,565
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology